Nasdaq-listed Rocket Pharmaceuticals has hired Martin Wilson as general counsel, chief compliance officer (CCO) and senior vice president.
Before joining the company, Wilson was general counsel and chief corporate officer at Ichnos Sciences, a role in which he oversaw the company’s legal, compliance, business development, human resources and IT functions. He helped establish Ichnos as an independent corporate entity and set up its corporate structure.
Before Ichnos, Wilson was general counsel, CCO, corporate secretary and head of human resources at Teligent. He was previously vice president and assistant general counsel at Endo Pharmaceuticals following the acquisition of Par Pharmaceuticals. He filled a number of positions of increasing responsibility – including CCO – at Par over 11 years with the company. Earlier in his career, he worked in the licensing group at Schering-Plough.
Rocket Pharmaceuticals is a clinical-stage company working on genetic therapies for rare childhood disorders. CEO Gaurav Shah says in a statement: ‘The Rocket family is thrilled to welcome Martin to our talented executive leadership team as we advance our world-class pipeline of gene therapies and unlock cures for patients facing devastating rare disease.
‘Martin’s vast legal and compliance expertise, coupled with exceptional leadership experiences at life science companies of varying sizes, scales our existing capabilities as we rapidly expand in support of our ambition to seek gene therapy cures.’